IP
OPRX icon

Intellectus Partners’s OptimizeRx OPRX Stock Holding History

Intellectus Partners’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-65,000
Closed -$1.17M – 432
2018
Q3 		$1.17M Buy
+65,000
New +$819K 0.41% 62

Other funds holding OPRX

PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
VCM
Venator Capital Management Toronto, Ontario, Canada $48.7M AUM 87.97% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

Intellectus Partners's OPRX Position: Q4 2018 in Review

Intellectus Partners sold out of OptimizeRx (OPRX) in Q4 2018, closing a stake of 65,000 shares — an estimated $1.17M sold.

Intellectus Partners first reported a position in OPRX in Q3 2018 and held it in 1 quarter. The position peaked at $1.17M in Q3 2018. 38 funds tracked by Wall St. Rank hold OPRX as of Q4 2018.

  • Intellectus Partners reported no remaining OptimizeRx position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 65,000 OptimizeRx shares in Q4 2018, an estimated $1.17M.
  • Intellectus Partners first reported a position in OptimizeRx in Q3 2018 and held it in 1 quarter.
  • Intellectus Partners's OptimizeRx position peaked at $1.17M in Q3 2018.
  • 38 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.